GeneHealth - Your precision medicine

Laron Syndrome

Disease Details

Family Health Simplified

Buy Membership

Description: Laron syndrome is a rare genetic disorder caused by growth hormone receptor insensitivity, leading to short stature and resistance to cancer and diabetes.
Type: Laron syndrome is an autosomal recessive disorder.
Signs And Symptoms: Laron syndrome, also known as growth hormone insensitivity, is a rare genetic disorder. Below are the signs and symptoms associated with the condition:

1. **Short Stature**: This is the most prominent feature, with individuals significantly shorter than average for their age.
2. **Delayed Bone Age**: Bone development may be delayed compared to chronological age.
3. **Distinct Facial Features**: These can include a prominent forehead, underdeveloped nasal bridge, and a small chin.
4. **Hypoglycemia**: Low blood sugar levels can occur, especially during infancy.
5. **Delayed Puberty**: Compared to peers, individuals with Laron syndrome often experience delayed onset of puberty.
6. **Obesity**: There is a tendency towards increased body fat and decreased muscle mass.
7. **Small Hands and Feet**: Compared to the rest of their body, individuals may have smaller extremities.

"Laron syndrome, nan." does not add any further context or clarify additional conditions; hence no additional relevant information is provided.
Prognosis: Laron syndrome is a rare genetic disorder characterized by insensitivity to growth hormone, leading to short stature and other clinical features. The prognosis for individuals with Laron syndrome varies but can be favorable with appropriate management.

Prognosis:
- Lifespan: Generally, individuals have a normal life expectancy.
- Height: Patients typically have a significantly shorter stature due to the lack of growth hormone activity.
- Quality of Life: With appropriate medical care, including growth hormone receptor analogs and other supportive treatments, many individuals can lead relatively normal lives.

Treatment and close medical supervision can significantly improve the outcomes and quality of life for those affected by Laron syndrome.
Onset: Laron syndrome, a rare genetic disorder characterized by insensitivity to growth hormone, typically presents symptoms from birth or in early infancy. The hallmark feature is significantly short stature, often becoming more apparent as the child grows.
Prevalence: The prevalence of Laron syndrome, a rare genetic disorder, is not well-documented but is estimated to be approximately 1 in 2 million people worldwide. Notable clusters of cases have been reported in regions such as Ecuador, Israel, and certain Mediterranean countries.
Epidemiology: Laron syndrome, also known as primary growth hormone insensitivity, is a rare genetic disorder characterized by an insensitivity to growth hormone due to mutations in the growth hormone receptor (GHR) gene. Epidemiologically, it is most commonly documented in populations with a high degree of consanguinity, such as in certain communities in Ecuador and Israel, but can appear worldwide.

Prevalence: The exact prevalence of Laron syndrome is not well-documented, but it is considered extremely rare with only a few hundred cases reported globally.

Incidence: Specific incidence rates are not widely published due to the rarity of the disorder. Most identified cases come from well-defined populations, so global incidence rates are difficult to estimate.

Note: If "nan" was an error or abbreviation, additional context might be necessary to address specific questions accurately.
Intractability: Laron syndrome, also known as growth hormone insensitivity syndrome, is a rare genetic disorder resulting in short stature and other metabolic anomalies. As of current medical knowledge, there is no cure for Laron syndrome, making it intractable in terms of complete eradication. However, some aspects of the condition can be managed with treatments such as recombinant insulin-like growth factor 1 (IGF-1) therapy, which can help improve growth and metabolic function.
Disease Severity: Laron syndrome, also known as growth hormone insensitivity syndrome, primarily affects growth and results in short stature.

- Disease Severity: The severity of Laron syndrome can vary. It typically leads to significantly shorter stature than average, but it does not usually affect life expectancy or intelligence. Patients may experience hypoglycemia (low blood sugar) as children and have an increased risk of obesity in adulthood.

"nan" doesn't seem applicable in this context. If you need further details or clarification, please provide more context or specify the information you need.
Healthcare Professionals: Disease Ontology ID - DOID:9521
Pathophysiology: Under normal circumstances in humans, growth hormone (GH) is released in a pulsatile fashion from cells known as somatotrophs in the anterior pituitary gland. These pulses of GH are regulated by cells in the hypothalamus, via the release of growth hormone-releasing hormone (GHRH) into the hypothalamohypophysial system when stimulated by insulin, ghrelin, glucagon, arginine, deep sleep, exercise, fasting, sex hormone release during puberty, and a host of other factors. GH release is inhibited by somatostatin (GHIH), IGF-1, hyperglycemia, and glucocorticoids. Once released, the GH molecules travel through the bloodstream and eventually bind to GH receptors on the surface of cells composing bodily organs and tissues. One major site of action for GH is in the liver, where it stimulates gluconeogenesis and the release of IGF-1 through the JAK-STAT signaling pathway. IGF-1 promotes growth in a variety of tissues throughout the body, especially bone mineralization, and provides negative feedback on GH release. GH results in increased muscle mass, lipolysis, and protein synthesis. Obesity and increased adipose tissue, especially visceral fat, results in reduced GH secretion. There is a natural age-related decline in the GHRH-stimulated release of GH.
Carrier Status: Carrier status for Laron syndrome is typically related to a mutation in the GHR (growth hormone receptor) gene. Laron syndrome is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an individual with Laron syndrome usually each carry one copy of the mutated gene but typically do not show signs and symptoms of the condition themselves. Hence, they are called carriers.
Mechanism: Laron syndrome, also known as growth hormone insensitivity syndrome, is primarily caused by mutations in the growth hormone receptor (GHR) gene. This results in an inability of the body to respond to growth hormone (GH), leading to short stature and other related symptoms.

The molecular mechanisms of Laron syndrome are as follows:
1. **Mutations in the GHR Gene**: The most critical factor is mutations in the GHR gene, which encodes the growth hormone receptor. These mutations may result in truncated receptors, receptors with impaired binding affinity, or receptors that are unable to transduce the GH signal inside the cell.

2. **Defective Signal Transduction**: GH binding to its receptor normally triggers a cascade of intracellular signaling pathways involving the JAK-STAT (Janus kinase-signal transducer and activator of transcription) pathway. In Laron syndrome, due to defective receptors, this signaling pathway is disrupted, preventing the downstream effects of GH, such as the production of insulin-like growth factor 1 (IGF-1).

3. **Reduced IGF-1 Levels**: IGF-1, produced in the liver and other tissues in response to GH, plays a crucial role in growth and development. In Laron syndrome, because of the failure of GH signaling, IGF-1 levels are significantly reduced, leading to impaired growth and other metabolic disturbances.

4. **Secondary Molecular Effects**: The lack of IGF-1 due to impaired GH signaling can lead to downstream effects on various biological processes, including cellular growth, differentiation, and metabolism.

Together, these mechanisms account for the clinical manifestations of Laron syndrome, which include short stature, distinctive facial features, and, in some cases, metabolic anomalies.
Treatment: Administration of GH has no effect on IGF-1 production, therefore treatment is mainly by biosynthetic IGF-1. IGF-1 must be taken before puberty to be effective.The drug product Increlex (mecasermin), developed by the company Tercica, purchased by Ipsen, was approved by the US Food and Drug Administration in August 2005 for replacing IGF-1 in patients who are deficient.IPLEX (Mecasermin rinfabate) is composed of recombinant human IGF-1 (rhIGF-1) and its binding protein IGFBP-3. It was approved by the U.S. Food and Drug Administration (FDA) in 2005 for treatment of primary IGF-1 deficiency or GH gene deletion. Side effects from IPLEX are hypoglycemia. IPLEX's manufacturing company, Insmed, after selling its protein production facility, can no longer develop proteins, thus can no longer manufacture IPLEX as of a statement released in July 2009.
Compassionate Use Treatment: Laron syndrome, a rare genetic disorder caused by mutations in the growth hormone receptor (GHR) gene, leads to insensitivity to growth hormone (GH). This results in short stature and various metabolic anomalies.

### Compassionate Use Treatment
In some cases, compassionate use treatment may involve:
- **Insulin-like Growth Factor 1 (IGF-1):** Recombinant IGF-1 (mecasermin) therapy is the primary treatment and is provided under compassionate use for patients who meet specific criteria.

### Off-Label or Experimental Treatments
Given the rarity and complexity of Laron syndrome, off-label or experimental treatments are limited but might include:
- **Recombinant Human IGF-1:** While mecasermin is specifically approved for IGF-1 deficiency, it is utilized off-label for Laron syndrome.
- **Gene Therapy:** Experimental approaches in gene therapy are under investigation to correct the underlying genetic defect.
- **GH Therapy:** Although not effective in traditional forms, some experimental studies explore modified formulations or adjunctive therapies to enhance GH receptor activity.

It's essential for patients to consult with specialized healthcare providers to explore these options, as they often require careful monitoring and personalized adjustments.
Lifestyle Recommendations: Laron syndrome, also known as Growth Hormone Insensitivity Syndrome, is a rare genetic disorder characterized by the body's inability to utilize growth hormone. Lifestyle recommendations for individuals with Laron syndrome typically include:

1. **Regular Monitoring:** Regular check-ups with a healthcare provider, including endocrinologists, to monitor growth, development, and general health.
2. **Nutritional Support:** Balanced diet with adequate nutrients to support overall health. Nutritional counseling may be helpful.
3. **Physical Activity:** Engaging in appropriate physical activities to promote strength, flexibility, and cardiovascular health while being mindful of physical limitations.
4. **Psychosocial Support:** Counseling or support groups to address any social or emotional challenges, as shorter stature may have psychological impacts.
5. **Medical Management:** Compliance with any prescribed medications or treatments, including recombinant IGF-1 therapy, if prescribed by a healthcare provider.
6. **Preventive Care:** Staying on top of vaccinations and regular screening tests to catch any related health issues early.

Maintaining an open line of communication with healthcare providers and following their recommendations is crucial for managing Laron syndrome effectively.
Medication: Laron syndrome, also known as growth hormone insensitivity syndrome, typically does not respond to traditional growth hormone treatments. Instead, treatment often involves the use of recombinant insulin-like growth factor 1 (IGF-1) therapy, specifically mecasermin (brand name Increlex). This medication helps promote growth and development in affected individuals. Regular monitoring by healthcare professionals is essential to manage potential side effects and ensure proper dosing.
Repurposable Drugs: Laron syndrome, a rare genetic disorder characterized by insensitivity to growth hormone, has limited treatment options. One of the primary treatments involves recombinant insulin-like growth factor 1 (IGF-1) to promote growth and manage symptoms. Currently, there are no widely recognized repurposable drugs for Laron syndrome. Research is ongoing to explore potential therapies.
Metabolites: Laron syndrome, also known as primary growth hormone insensitivity, involves a spectrum of biochemical imbalances, primarily relating to the growth hormone (GH) and insulin-like growth factor 1 (IGF-1) axis. Patients with Laron syndrome typically have elevated levels of circulating GH due to its ineffective action on target tissues. However, there is a marked deficiency in IGF-1, which is crucial for normal growth and development. Additionally, other metabolites related to the GH/IGF-1 pathway might be dysregulated, and there can be alterations in glucose, lipid metabolism, and bone density markers. Elevated GH alongside low IGF-1 in the presence of short stature is a hallmark of this condition.
Nutraceuticals: Laron syndrome, a rare genetic disorder, is characterized by an insensitivity to growth hormone due to mutations in the growth hormone receptor (GHR) gene. Nutraceuticals may not play a direct role in the treatment of Laron syndrome, as the primary therapy involves recombinant insulin-like growth factor 1 (IGF-1) to promote growth and development. However, ensuring adequate overall nutrition can support general health and well-being. Always consult a healthcare provider for personalized advice and treatment options.
Peptides: Laron syndrome, also known as Laron-type dwarfism, is caused by a mutation in the growth hormone receptor (GHR) gene, leading to insensitivity to growth hormone. Peptide-based therapies for Laron syndrome primarily revolve around the use of insulin-like growth factor 1 (IGF-1) rather than growth hormone itself, as the body cannot utilize growth hormone properly.

Currently, there are no established nanotechnology-based approaches (nanotechnologies) specifically targeting Laron syndrome. Most treatments focus on recombinant IGF-1 administration to manage growth and metabolic issues.